Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
November 2019
-
Press Release
Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only… -
Key Release
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically… -
Story Discovery
Can data from a heart disease trial lead to a potential cancer treatment?
Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.
October 2019
-
Key Release
Novartis announces AVXS-101 intrathecal study update
FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal studyAdverse events that might be expected from the pre-clinical… -
Press Release
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
New Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their… -
Key Release
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc… -
Key Release
Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu
Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)… -
Key Release
Novartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA
Chiffre d’affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: Cosentyx: USD 937 millions (+27% tcc), avec une forte demande dans toutes les indications et… -
Press Release
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
REACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD… -
Featured News
Pride @ Novartis 2019
As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
-
Press Release
Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results… -
Featured News
World Sight Day 2019